Dr. Richard Foemmel of Nashua was recently appointed chair of Rivier’s Board of Trustees. He has served as a member of the board since 2008 and as vice chair for the past two years.
“We are pleased to welcome Dr. Foemmel’s leadership, which will be invaluable as we continue to move forward with our strategic initiatives,” said Sister Paula Marie Buley, IHM, president. An international entrepreneur and leader, Dr. Foemmel has developed and managed commercial operations in Germany, France, Spain, and Italy, and brings extensive experience in initiating global partnerships to the board. His experience includes key leadership roles with the world’s leading biotech, diagnostic laboratories, and medical research companies. Dr. Foemmel served as president and CEO, and currently serves as director of the board at DecImmune Therapeutics, Inc. of Boston, Mass., an early-stage drug discovery company, providing therapeutics for inflammatory and autoimmune diseases. He founded and served as president and CEO of CytoLogix Corporation of Cambridge, Mass., a medical products company focused on development and commercialization of cellular diagnostic instrument and reagent systems. Prior to this, he directed operations for global health care and testing firms, Dianon Systems, Inc. of Stratford, Conn.; and Abbott Laboratories of Chicago, Ill. A chemist and research scientist, Dr. Foemmel holds a Ph.D. in biological chemistry from the University of Michigan in Ann Arbor, Mich., an M.B.A. from the Stern School of Business at New York University in New York, N.Y., and a bachelor’s in chemistry from Cornell College in Mt. Vernon, Iowa. He currently serves as vice president of the board of the Symphony NH.